CD28 and cancer: The reversion of exhaustion of T cells is CD28-dependent and ultimately enhances the sensitivity of cancer cells to checkpoint blockade.TCR-CD28 co-stimulation is known to activate the CBM complex/NF-κB pathway in T cells, indicating that NF-κB could have a role in immune checkpoint therapy, although this needs further investigation (34).